Huntington Disease Mutation Analysis
Huntington’s disease (HD) is a rare, autosomal dominant genetic disease affecting 4-7 European ancestry individuals per 100,000. It is less common in other populations, including Chinese, Japanese, and African. HD is a neurodegenerative disease characterized by chronic progressive chorea (involuntary jerking or twitching movements), cognitive impairment, mood disorders, behavioral changes, and, ultimately death. Median survival after onset of symptoms is 17-20 years. Onset age varies widely with a mean age of approximately 40, although ~5% become symptomatic at a younger age. There is no current treatment or therapy for HD.
Clinical testing strategies for HD include, 1) confirmation testing to diagnose the disease, 2) presymptomatic, predictive testing of carrier status, and 3) prenatal testing to determine status of the fetus with a family history of HD. Several HD-like disorders may be mistaken for HD including Huntington disease-like syndrome (there are four types of HDL syndrome, termed HDL1 through HDL4), early-onset familial Alzheimer’s, and Creutzfeldt-Jakob disease. Confirmation of disease status provides proper patient care and genetic information for at-risk relatives. Predictive testing determines genetic risk for individuals who have a family history of HD. Prenatal testing is not frequently performed; instead, testing before pregnancy for at-risk individuals is preferred. Prenatal testing represents 0.5% of all HD tests performed.
HD is caused by mutations in the HTT (HD) gene located on chromosome 4, specifically 4p16.3 region. The HTT gene provides instructions for making the protein huntington; although of unknown function, it may play a role in brain nerve cells.
The molecular basis of HD provides key factors for detection and predictive patient impacts. The disease is characterized at the molecular level by a trinucleotide expansion (CAG) in the HTT coding region. Testing is comprised of polymerase chain reaction and Southern blot analyses to determine length variants of an individual’s alleles. The Normal HTT allele contains 26 or fewer repeats. Mutations from this type are extremely rare and thus, low spontaneous occurrence of the disease is observed. Intermediate alleles have expanded repeat regions with 27-35 repeats. Carriers of intermediate alleles may not have symptoms of HD but have increased risk of HD in descendants. Full mutation alleles (HD) are defined as 36+ repeats and are considered at-risk of developing HD. The full allele mutation is further classified into: reduced-penetrance and full-penetrance alleles. An individual with reduced-penetrance alleles are at-risk for HD but may or may not develop symptoms. An individual with full-penetrance is associated with certain development of HD in their lifetime.
- Diagnose Huntington disease (confirmation of disease)
- Presymptomatic testing to predict carrier status for inheriting the disease
- Prenatal testing to determine carrier status of fetus
- Normal: Rules out diagnosis of HD or premature carrier status
- Intermediate: An individual with an allele within the range of 27-36 CAG repeats is not at risk of developing symptoms, but may lead to an increased risk of HD in descendants
- Full mutation: An individual is at risk of developing HD in their lifetime
- Reduced penetrance: Detection of one normal allele and one reduced penetrance allele; individual may or may not develop disease symptoms; offspring are at risk for inheriting a disease causing allele
- Full penetrance: Detection of one or two disease-causing alleles; individual is predicted to develop HD, and offspring have a 50 percent chance of inheriting the disease allele. There is no difference in age of onset, disease symptoms, or progression in individuals with one or two fully penetrant alleles
Note: Mosaicism may be detected; however, the level is typically not significant to compromise interpretation of disease status.
- Normal alleles:<26 CAG repeats
- Intermediate alleles: 27-35 CAG repeats
- Full mutation alleles: >36 CAG repeatsReduced-penetrance: 36-39 CAG repeats
- Full-penetrance: >40 CAG repeats
Whole Blood EDTA (Lavender), ACD (Yellow) or Bone Marrow.
Stability
- Ambient: 3-5 days
- Refrigerated: 5-7 days
- Frozen: 30 days
3-5 days.
- Genet Med. 2011 Sep 26. [PMID: 21952430]
- Expert Rev Mol Diagn. 2006 Jul;6(4):587-96. [PMID: 16824032]
- NeuroRx. 2004 Apr;1(2):255-62. [PMID: 15717026]
- Expert Rev Mol Diagn. 2006 Jul;6(4):587-96. [PMID: 16824032]
- Neuromolecular Med. 2003;4(1-2):7-20. [PMID: 14528049]